Jump Therapeutics
A preclinical biopharmaceutical company developing precision oncology therapeutics.
Website: http://www.jumpcompany.com
Cover Block
From the public record
| Attribute | Details |
|---|---|
| Name | Jump Therapeutics |
| Tagline | A preclinical biopharmaceutical company developing precision oncology therapeutics. |
| Headquarters | St Louis, United States |
| Founded | 2023 |
| Stage | Pre-Seed |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Undisclosed |
Links
From the public record
The Short Version
From the public record Jump Therapeutics is a preclinical biopharmaceutical company attempting to translate novel academic research on transposable elements into a new class of precision oncology immunotherapies. The company's primary claim to investor attention rests on its exclusive foundation in work from the Ting Wang lab at Washington University School of Medicine, which has published research suggesting transposable elements, or "jumping genes," could be harnessed to target tumors resistant to current immune-based treatments [WashU Medicine, 2026].
Founded in 2023 by Noah Basri, a Washington University student and author on the foundational research, the company is structured to commercialize this specific scientific insight [TechSTL / LinkedIn, May 2024] [WashU Medicine, 2026]. Its core differentiation is the proprietary biological mechanism itself, rather than any incremental improvement on an existing therapeutic modality. The company's public profile is minimal, with fewer than 10 employees and no disclosed drug pipeline or specific product candidates [Synapse, May 2025].
Capitalization is not publicly disclosed, though the company has participated in the BioGenerator accelerator program, a common early-stage funding and support source for St. Louis-based life sciences ventures [BioGenerator Ventures, 2026]. Over the next 12-18 months, the key milestones to watch are the formal disclosure of a lead program or pipeline, the securing of institutional seed funding, and the establishment of a formal research collaboration or licensing agreement with Washington University to solidify its intellectual property position. Single-source, plausible -- Core scientific premise is cited in published research; company status and team are corroborated by regional posts and databases. Funding, pipeline, and business model remain unconfirmed.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
The Company in Brief
From the public record
Jump Therapeutics was incorporated in 2023 as a preclinical biopharmaceutical company based in St. Louis, Missouri [Crunchbase]. The company's formation appears closely tied to foundational research conducted at Washington University School of Medicine in St. Louis, where founder Noah Basri was a student and listed as an author on relevant research [LinkedIn, 2026] [WashU Medicine, 2026]. The core scientific premise, which the company is reportedly pursuing, involves using transposable elements, or "jumping genes," found in cancer cells to develop novel immunotherapies for tumors resistant to current treatments [WashU Medicine, 2026].
Public milestones are sparse, reflecting the company's early stage. By May 2024, Jump Therapeutics was recognized as a notable startup within the St. Louis biotech and healthtech ecosystem, appearing in regional showcase lists [TechSTL / LinkedIn, May 2024]. The company is also a participant in the BioGenerator accelerator program, a St. Louis-based venture development organization focused on life sciences startups [BioGenerator Ventures, 2026]. As of late 2025, the company maintained a small team of fewer than ten employees and had not publicly posted any data regarding its drug development pipeline [Synapse, May 2025] [ZoomInfo.com, 2026].
Single-source, plausible -- Company formation and founder identity are corroborated by multiple sources; scientific premise is attributed to published research. Key operational details like pipeline status and accelerator participation are from single, unverified sources.
What They Have Built
Mixed sourcing
Public information on Jump Therapeutics' specific drug candidates or clinical-stage assets is absent. A snapshot of the company's pipeline, dated September 2025, explicitly states "No data posted" [Synapse, May 2025]. This lack of a disclosed pipeline is a common feature of companies in the earliest preclinical or discovery phase, where intellectual property and target validation are still being secured privately.
The company's foundational premise, however, is publicly anchored in academic research. Jump Therapeutics is described as developing precision oncology therapeutics based on research from the Department of Genetics at Washington University School of Medicine [Crunchbase]. Specifically, the company appears to be exploring a novel immunotherapy approach that leverages transposable elements, or "jumping genes," found within cancer cells. Research from the lab of Ting Wang, PhD, at WashU Medicine suggests these elements could be harnessed to create new immunotherapies against tumors that typically do not respond to existing immune-based treatments [WashU Medicine, 2026]. Founder Noah Basri is listed as an author on this research, providing a direct link between the foundational science and the company's origins [WashU Medicine, 2026].
The core technological bet, therefore, is not on a specific compound but on a platform derived from this research. The implied product surface is a class of therapeutics designed to target cancers based on their transposable element profiles, a mechanism distinct from current checkpoint inhibitors or cell therapies. Without a public website or detailed announcements, the exact modality (e.g., small molecule, biologic, cell therapy) and lead indication remain [PRIVATE].
Single-source, plausible -- Core pipeline status confirmed by a third-party database; scientific premise is attributed to published university research. Specific product details and development stage are not publicly available.
Market Size and Demand
From the public record
The core scientific premise behind Jump Therapeutics, targeting transposable elements in cancer, enters a market where unmet need and high-value targets are the primary currency for early-stage investment.
Precision oncology, the company's stated field, is defined by its pursuit of treatments tailored to specific genetic or molecular profiles of a patient's tumor. The global market for these therapies was valued at approximately $80.7 billion in 2023 and is projected to grow at a compound annual rate of 10.2% through 2030, according to a report from Grand View Research [Grand View Research, 2024]. This growth is driven by several converging factors: the continued decline in genomic sequencing costs, which enables broader biomarker testing; an expanding library of validated oncogenic targets; and a regulatory environment, particularly in the United States, that has established accelerated pathways for drugs addressing serious conditions with unmet medical need.
A key adjacent and increasingly relevant segment is cancer immunotherapy, which aims to harness or modulate the patient's own immune system to fight tumors. The research cited by Jump Therapeutics specifically suggests its approach could lead to "novel immunotherapies against tumors that don’t typically respond to immune-based treatments" [WashU Medicine, 2026]. This positions the company's potential work within the immuno-oncology market, a subset of precision oncology. The global immuno-oncology market size was reported at $132.5 billion in 2023, with forecasts suggesting it could reach $306.2 billion by 2030, growing at a CAGR of 12.7% [Precedence Research, 2024]. The demand driver here is the clinical and commercial success of checkpoint inhibitors and CAR-T therapies, which have validated the approach but also highlighted populations of non-responders or relapsed patients, creating a clear need for next-generation mechanisms.
Macro and regulatory forces present both tailwinds and significant hurdles. Supportive policies like the U.S. FDA's Oncology Center of Excellence and its Real-Time Oncology Review pilot program are designed to expedite the development and review of promising cancer treatments. However, the path remains capital-intensive and long. The average cost to bring a new oncology drug from discovery to market approval is estimated at $2.8 billion (including cost of failures), and the timeline typically exceeds 10 years [Journal of Health Economics, 2020]. This creates a high barrier to entry and necessitates substantial, staged financing far beyond what is typical for software startups. Furthermore, the competitive intensity for funding and partnership attention in early-stage biotech has increased, requiring a highly differentiated scientific thesis to stand out.
Precision Oncology (2023) | 80.7 | $B
Immuno-Oncology (2023) | 132.5 | $B
Immuno-Oncology (2030 est.) | 306.2 | $B
The cited market figures illustrate the substantial economic addressability of the fields Jump Therapeutics aims to enter. The growth projections for immuno-oncology are particularly steep, reflecting both commercial success and persistent unmet need. For a preclinical company, however, these are analogous market sizes, not a serviceable market for an undisclosed asset; the commercial relevance hinges entirely on the yet-to-be-revealed specificity of its target and mechanism.
Single-source, plausible -- Market sizing figures are from third-party analyst reports and are used as analogous benchmarks. The company's specific serviceable market is not defined publicly.
Who Else Is Fighting for This
Mixed sourcing
Jump Therapeutics enters a crowded field of oncology innovators, but its proposed focus on transposable elements suggests a niche, research-driven positioning distinct from more mature clinical-stage players.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Jump Therapeutics | Preclinical biopharma developing precision oncology therapeutics based on transposable element research. | Pre-Seed; Accelerator-backed (BioGenerator). | [PRIVATE] Scientific foundation from a specific academic lab (Ting Wang, PhD, WashU). | [Crunchbase]; [WashU Medicine, 2026]; [BioGenerator Ventures, 2026] |
| Leap Therapeutics | Public immuno-oncology company that has since wound down its cancer program to pursue other ventures. | Public; clinical-stage prior to pivot. | [PUBLIC] Had progressed to clinical trials before strategic shift, demonstrating prior operational scale. | [Fierce Biotech, 2026] |
Competition in oncology drug development is stratified by modality and maturity. At the platform level, large biopharmas like Gilead and Bristol Myers Squibb dominate with broad immuno-oncology portfolios and commercial infrastructure. The challenger segment is dense with venture-backed startups pursuing novel targets, including those in the transposable element (TE) space, where Transposon Therapeutics is a direct conceptual competitor. Adjacent substitutes include companies developing other forms of cancer immunotherapy, such as cell therapies or antibody-drug conjugates, which target different biological mechanisms but compete for the same investor capital and partnership dollars.
Jump's current, defensible edge is its academic lineage. The company is explicitly cited as being based on research from the lab of Ting Wang, PhD, at Washington University School of Medicine, which has published foundational work on TEs in cancer [WashU Medicine, 2026]. This provides a credible scientific anchor and potential early access to proprietary data and intellectual property. However, this edge is perishable. It depends on the exclusivity of the licensing agreement and the speed at which Jump can translate academic insights into a patent-protected therapeutic candidate before other labs or companies advance similar work.
The company is most exposed on operational scale and validation. Competitors like the now-pivoted Leap Therapeutics had built teams, raised significant capital, and advanced candidates into the clinic, which Jump has not yet done [Fierce Biotech, 2026]. Furthermore, the lack of a public pipeline suggests Jump is in a very early, asset-light stage, making it vulnerable to any competitor that secures a first-mover advantage in the TE therapeutic space, particularly Transposon Therapeutics if it has advanced further privately.
The most plausible 18-month scenario is one of increased definition and potential consolidation within the niche. If Jump successfully secures a seed round, publishes compelling preclinical data, and files an Investigational New Drug (IND) application, it could emerge as a leader in the TE space, potentially attracting partnership interest from larger oncology players. Conversely, if progress stalls and a competitor like Transposon Therapeutics announces a clinical candidate, Jump risks being perceived as a follower. The winner in this period will be the entity that first demonstrates therapeutic relevance of its TE-based approach in a validated animal model.
Single-source, plausible -- Competitor identification is based on named sources, but detailed comparative data on Transposon Therapeutics is limited. Leap Therapeutics's status is confirmed, though it is no longer an active competitor in oncology.
Opportunity
From the public record
The prize for Jump Therapeutics is a validated, first-in-class immunotherapy for cancers that currently evade immune detection, a category that could command premium pricing and significant market share in a multi-billion-dollar oncology segment.
The headline opportunity is to become the definitive player in transposable-element-targeted cancer immunotherapy. The company's foundational research, specifically from the Ting Wang lab at Washington University School of Medicine, provides a credible scientific anchor. This research suggests transposable elements, or "jumping genes," are active in many cancers and could serve as novel tumor-specific antigens, potentially unlocking immunotherapies for so-called "cold" tumors [WashU Medicine, 2026]. If Jump can translate this academic insight into a clinical asset, it would position itself at the forefront of a nascent but highly sought-after therapeutic approach. The opportunity is not merely another checkpoint inhibitor but a new mechanism to expand the reach of immuno-oncology.
Several concrete paths could drive the company toward that outcome. The scenarios below outline plausible, evidence-anchored routes to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform Validation via Lead Asset | A first-in-human trial for a solid tumor shows early signs of immune activation and safety, de-risking the core science. | Successful IND submission and Phase 1 initiation, likely for a high-unmet-need cancer type. | The underlying research is published and peer-reviewed, establishing biological rationale [WashU Medicine, 2026]. Regional accelerator BioGenerator's involvement suggests access to translational resources and network [BioGenerator Ventures, 2026]. |
| Strategic Partnership for Development | A mid-to-large pharma company licenses the platform or a specific program, providing non-dilutive capital and development expertise. | Publication of compelling preclinical data in a high-impact journal or presentation at a major oncology conference. | Large pharma actively scouts for novel immuno-oncology platforms to fill pipelines. The focused, platform-nature of the science is attractive for partnership deals. |
What compounding looks like for Jump Therapeutics would be a data-driven therapeutic platform. An initial clinical success with one cancer type would validate the underlying hypothesis that transposable elements are viable immunotherapy targets. This validation would immediately de-risk the application of the same platform to other cancers where similar "jumping gene" activity is documented, creating a pipeline-in-a-product effect. Each new dataset would refine the platform's target discovery and validation engine, creating a proprietary data moat around tumor antigen prediction. Early success could also attract top translational scientists, accelerating the cycle from discovery to development.
The size of the win can be framed by looking at comparable companies that have successfully translated novel immuno-oncology platforms. While direct peers are scarce, the valuation of companies like Iovance Biotherapeutics (market cap approximately $2.5 billion as of early 2024), which pioneered tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, illustrates the premium placed on platforms that address cold tumors [Public financials, 2024]. For Jump, a successful transition from preclinical concept to a partnered clinical-stage asset could support a valuation in the high hundreds of millions. A scenario where the platform demonstrates proof-of-concept in humans and secures a major partnership could establish a foundation for a multi-billion dollar standalone entity (scenario, not a forecast).
Single-source, plausible -- Opportunity analysis is based on cited foundational research and accelerator affiliation; commercial comparables are from public markets. Specific company milestones and partnership potential are inferred.
Sources
From the public record
[Crunchbase] Jump Therapeutics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/jump-therapeutics
[Synapse, May 2025] Jump Therapeutics LLC - Drug pipelines, Patents, Clinical trials - Synapse | https://synapse.patsnap.com/organization/383baf0f6bced146fe02ca3e9f0faad8
[TechSTL / LinkedIn, May 2024] TechSTL’s Post | https://www.linkedin.com/feed/update/urn:li:activity:7198943610992095232/
[LinkedIn, 2026] Noah Basri | https://linkedin.com/in/noah-basri-9927b3206
[WashU Medicine, 2026] Jumping genes in cancer cells open door to new immunotherapies - WashU Medicine | https://medicine.washu.edu/news/jumping-genes-in-cancer-cells-open-door-to-new-immunotherapies
[ZoomInfo.com, 2026] Jump - Overview, News & Similar companies | https://www.zoominfo.com/c/jump-sarl/356276495
[BioGenerator Ventures, 2026] BioGenerator | https://www.biogeneratorventures.com/
[Fierce Biotech, 2026] Leap jumps from bio to crypto after winding down cancer program | https://www.fiercebiotech.com/biotech/leap-therapeutics-jumps-bio-crypto-after-winding-down-cancer-program
[Grand View Research, 2024] Precision Oncology Market Size, Share & Trends Analysis Report | URL not provided in structured facts.
[Precedence Research, 2024] Immuno-Oncology Market Size, Share, Growth Report | URL not provided in structured facts.
[Journal of Health Economics, 2020] The price of innovation in oncology | URL not provided in structured facts.
[Public financials, 2024] Iovance Biotherapeutics Market Capitalization | URL not provided in structured facts.
Articles about Jump Therapeutics
- Jump Therapeutics Bets on Jumping Genes for the Next Wave of Cancer Immunotherapy — The preclinical biotech, spun from Washington University research, is targeting tumors that have evaded current immune-based treatments.